faun1083

Faun1083 is a novel small molecule therapeutic in preclinical development by Fauna Bio for the treatment of heart failure with preserved ejection fraction (HFpEF) and pulmonary heart disease. The drug was discovered using Fauna Bio’s AI-powered Convergence platform, which leverages comparative genomics and insights from hibernating mammals—specifically, the cardiac protection mechanisms of the 13-lined ground squirrel. Faun1083 has demonstrated efficacy in multiple preclinical animal models relevant to HFpEF and pulmonary hypertension, showing improvement in diastolic dysfunction as well as strong potency, selectivity, pharmacokinetic properties suitable for oral dosing, and a favorable toxicity profile. Its mechanism of action remains undisclosed but is described as novel and differentiated from existing therapies[1][2][3][4][5][7].

Other names

Faun1083Faun-1083Faun 1083